ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TRX Tissue Regenix Group Plc

61.50
0.00 (0.00%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00BNTXR104 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 61.50 61.00 62.00 61.50 61.50 61.50 58,537 08:00:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 29.49M -302k -0.0043 -143.02 43.4M
Tissue Regenix Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 61.50p. Over the last year, Tissue Regenix shares have traded in a share price range of 49.00p to 71.50p.

Tissue Regenix currently has 70,574,468 shares in issue. The market capitalisation of Tissue Regenix is £43.40 million. Tissue Regenix has a price to earnings ratio (PE ratio) of -143.02.

Tissue Regenix Share Discussion Threads

Showing 13776 to 13799 of 14750 messages
Chat Pages: Latest  554  553  552  551  550  549  548  547  546  545  544  543  Older
DateSubjectAuthorDiscuss
23/9/2021
09:54
Rocketblast - comments like that really don't help. I think we're all frustrated with the share price dragging it's heels - I certainly am, but at the moment directors are not buying
carrotandstick
23/9/2021
09:29
rocketblast

How do you know "more Directors buying soon" ? If this were to be true and it hasn't yet happened it means you would have insider information and both you and the Directors could "be done" for that. Would be nice to see Directors buying though - let's hope that does happen.

channel pirate
23/9/2021
09:10
spread has been quite wide last 48 hours....
emeraldzebra
23/9/2021
08:25
TRX more Directors buying soon as the current value is great.
rocketblast
17/9/2021
08:33
TRX revenue will ramp up as demand continues to increase. New Facilities will support rapid growth. Great price to get in and top up. Looking positive with news in the pipeline.
rocketblast
16/9/2021
07:59
One thing that worries me is their cash burn they say they only burnt 1.1 million in the last 6 months but cash position down to 6 million odd from around 13 million raised my view is they need to get their skates on I was expecting turnover of at least 8 millionSo a bit disappointed with the resultsThey must reach at least that in the next half to stop the cash burn Then what?
tnt99
15/9/2021
17:54
TRX are bow a great opportunity to top up at these great prices as demand increases and sales increase. Fill ya boots wgile you can..
rocketblast
14/9/2021
09:47
Loads of detail on the ARMS website from a surgeon and end user perspective on DCELL and VNEW. The reviews from the patients and surgeons are particularly enlightening as to the quality of the products.

ARMS reckon they can achieve sales of 30K units pa of this single TRX product line within 5 years in the US. Wondering what the global market could generate???!!!

gsg
14/9/2021
09:08
TRX which M&A company is putting the ruler over TRX. Must be a strong target for takeover before prices rise as results flow in. Watching and waiting …looking great.
rocketblast
13/9/2021
11:21
Well that simply shows the demand is there!
pennstreet
13/9/2021
09:17
Yes B1inkers, agree with your points. Could be there is no issue. Am throwing it out there given the DSI number is so high, I have very rarely seen a number this large hence my observation. If the 365 doesn't come down it tells us that it is WC intensive and may restrict OpCF generation as it grows. Will dig some more to understand why it's so high.
bertiebingo
13/9/2021
08:00
From the CEO's interim report/interview, I thought it was previous lack of processing capacity and inventory which had hampered the company's growth in the past. Hence the expansion of the San Antonio facility in order to increase stock and processing capacity, creating the four 'S' strategy for the future.
gsg
13/9/2021
07:35
Presumaby inventory is decellularised tissue, in cold storage until delivered.

Increase in cost of goods sold has kept pace with inventory, suggesting they are maintaining an operational buffer of around a year's stock. Meaning they're well placed to deal with an uptick in demand.

I expect obsolescence checks would be run annually by the auditirs and be fairly stringent, given materiality and risk of impairment.

b1inkers
12/9/2021
20:14
DSI = Days sales inventoryWhen it's high there is a risk of obsolescence therefore right offs (I don't know exactly what TRXs inventory is but I guess it's material for future surgerical use). If demand growth slows a company may need to slow production more than normal to stop inventory building therefore margins weaken due to negative.operating leverage (may not be the case here but often happens with industrials)
bertiebingo
12/9/2021
16:40
Bertie,

What's "DSI"?

TY

contact2fsnetcouk
12/9/2021
15:48
Anyone have a view or a comment from the company regarding the exceptionally high DSI which has remained around 365 days for the last 3 results. I did ask a question on last weeks InvestorMeetCompany but was too late for an answer.
bertiebingo
12/9/2021
10:58
Add for gold. I don't see this drifting any further
pennstreet
12/9/2021
10:26
I agree the future looks bright, but suspect we'll drift for a few weeks until the next update (just being realistic). Hold for gold.
baconlover
12/9/2021
10:16
Excellent video. Thanks GSGThe future is bright for TRX ;0)
pennstreet
11/9/2021
16:21
Apologies if this video has been posted before.





The Balancing Act

Did you know that approximately 300,000 women in the U.S. undergo surgical procedures for pelvic organ prolapse (POP) each year — and the prevalence increases with age? Many suffer in silence because of the perceived stigma associated with the condition, but treatment innovations are now available. ARMS Medical is providing innovative solutions for women’s pelvic health issues. Their pioneering technologies, including dCELL® Technology for pelvic floor surgery, may help women recover faster, and may lead to fewer complications, compared to older techniques.

Their innovative approach to pelvic floor surgery is based on the use of a next-generation tissue, DermaPure® and VNEW™, decellularized dermal allografts featuring patented dCELL® Technology which stimulate natural healing, minimize scarring, and are used to reinforce the repair of damaged tissue. DermaPure® and VNEW™ with dCELL® Technology have shown improved safety and efficacy in over 3,000 pelvic floor surgeries.

gsg
10/9/2021
14:05
Vadim Alexandre about the TRX report:


hxxps://audioboom.com/posts/7939600-vadim-alexandre-discusses-tissue-regenix-s-half-year-report

ultrasilva
10/9/2021
10:01
Added 1.2m
pennstreet
08/9/2021
13:00
Great interview. Clear strategy, ready to handle the onslaught as we emerge from the pandemic
pennstreet
08/9/2021
10:51
Nice one Penn. I'm quite a bit behind at 5m. If, a few of my other stocks reach target, I'll attempt to catch up here.
gsg
Chat Pages: Latest  554  553  552  551  550  549  548  547  546  545  544  543  Older

Your Recent History

Delayed Upgrade Clock